The Levels of Parathormone, Galcium and Inorganic Phosphore in CAPD Patients Treated with or without Phosphate Binder Agent and Calcitriol

Abstract

in the present study, we have measured serum parathormone (PTH), total calcium and inorganic phosphore levels in 14 CAPD patients treated with (seven patients) or without (seven patients) aluminum hydroxide and calcitriol. Blood samples were obtained immediately prior to and after a mean 3.7 months of CAPD therapy. In both groups, CAPD therapy caused significant decrease in the levels of mean serum PTH and inorganic phosphore, whole significantly increasing the levels of serum total calcium. Prior to CAPD therapy, the mean serum PTH, total calcium and inorganic phosphore levels were similar in the two groups. On the other hand CAPD therapy, in patients treated with aluminum hydroxide and calcitriol, the levels of mean serum PTH and inorganic phosphore were significantly lower (p<.0.05 and p<0.05 respectively) and the level of mean serum total calcium was significantly higher (p<0.01) that in patients who had not received these drugs. These data suggest that CAPD therapy is beneficial in control ing of serum PTH, calcium and inorganic phosphore levels, but these are not sufficient and requiring additional medications are generally reqiured.

Keywords

• CAPD
• Parathormone
• Serum calcium
• Inorganic phosphore
• Aluminum hydroxide
• Calcitriol.

Fosfat Baglayict Ajan ve Aktif D Vitamini Alan ve Almayan CAPD

Abstract

Bu gahsmada, aliuminyum hidroksit ve calcitriol alan (yedi hasta) ve almayan (yedi hasta) 14 CAPD hastasinda serum parathormon (PTH), total kalsiyum ve inorganik fosfor dlizeylerini dél¢tuk. Kan dérnekleri CAPD tedavisinden hemen Gnce ve ortalama 3.7 ay sonra alind. Her iki grupta da, CAPD tedavisi ortalama serum PTH ve inorganik fosfor dizeylerinde anlamh azalmaya ve serum total kalsiyum duzeyinde anlamli artisa neden oldu. CAPD tedavisi éncesindeki ortalama serum PTH, total kalsiyum ve inorganik fosfor diizeyleri her iki grupta benzerdi. Fakat, CAPD tedavisinden sonra aliiminyum hidroksit ve calcitriol alan hastalardaki ortalama serum PTH ve inorganik fosfor duzeyleri bu ilaclan almayan hastalardan anlamh olarak daha, dtisuk (sirasiyla p<0.05 ve p<0.05), serum total kalsiyum duzeyi ise anlamli olarak daha ytiksekti (p<0.01). Bu veriler, CAPD tedavisinin serum PTH, kalsiyum ve inorganik fosfor dtizeylerinin kontrollinde yararl oldugunu diistindtirmektedir, fakat bu etkiler yeterli degildir vegenellikle hastalara ilave ilaglarin verilmesi gereklidir.

Keywords

• CAPD
• Parathormon
• Serum kalsiyum
• Inorganik fosfor
• aliiminyum hidroksit
• Calcitriol.

References

1. 1.Blumenkrantz MJ Kopple JD Moran JK et al : Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 21 : 949-861, 1982.
2. 2.Blumenkraentz MJ Moran JK Coburon JW :; Peritoneal clearance during prolonged maintenance peritoneal dialysis in diabetic and nondiabetic patients (Abstract). Kidney Int 14: 671, 1987.
3. 3.Brown EM Wilson RE Eastman RC et al: Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 54 : 172-179, 1982.
4. 4.Cassidy MJD Owen JF Ellis HA et al: Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis. Q J Med 54 : 29-48, 1985.
5. 5Cunningham J Beer J Coldwell RD et al : Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant 7: 63-68, 1992.
6. 6.Delmez JA Slatopolsky E Martin KJ et al: Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int 21 : 862-867, 1983,
7. 7.Delmez JA Fallon MD Bergfeld MA et al : Continuous ambulatory peritoneal dialysis and bone. Kidney Int 30 : 379-384, 1986.
8. 8.Erbay B : Perkiitan Tenckhoff kateter yerlestirilmesi ve komplikasyonlar.. Ankara, Tip Biilteni 10 . 347-354, 1988.

9. 9.Gokal R Ramos JM Ellis HA et al : Histological renal osteodystrophy, and 25-hydroxycholecalciferol and aluminum levels in patients on continuous ambuiatory peritoneal dialysis. Kidney Int 23 ; 15-21, 1983.
10. 10.Hodsman AB Cordy PE Fraher LJ : Parathyroid hormone, vitamin D, and metabolic bone disease in dialysis patients. In Clinical Dialysis : Nissenson AR, Fine RN, Gentile DE (eds). Second edition, Prentice-Hall International Inc. pp 494-534, 1990.
11. 11.Martinez M Ausejo M Miguel JL et al: Comparative study between intact PTH and fragments of PTH in patients hemodialysis and CAPD. Perit Dial Int 11 : 137-140, 1991.
12. 12.Nolph KD Sorkin I Rubin J et al : Continuous ambulatory peritoneal dialysis : Three - year experience at one center. Ann Intern Med 92 : 609-613, 1980.
13. 13.Piraino B Bernardini J Holley J et al: Calcium mass transfer in peritoneal dialysis patients using 2.5 mEq/L calcium dialysate. Clin Nephrol 37 : 48-51, 1992.
14. 14.Rodriguez - Carmona A Selgas FR, Martinez M et al : Characteristics of the peritoneal mass transfer of parathormone patients under continuous ambulatory peritonea ldialysis therapy. Nephron 37: 21-24, 1984.
15. 15.Shusterman NH Wasserstein AG Morrison G et al: Controlled study of renal osteodystrophy in patients undergoing dialysis. Am J Med 82: 1148-1156, 1987.
16. 16.Silver J Naveh-Many T Mayer H et al: Regulation by vitamin D metabolities of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78 : 1296-1301, 1986.
17. 17.Zucchelli P Santoro A : Inorganic phosphate removal during different dialytic procedures. Int J Artif Organs 10 : 173-178, 1987.